{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-019592","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.465266+00:00","generated_at":"2026-06-23T03:20:26.368301+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues","bullets":["Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.","Adding fewer than 150 patients (total <300 with no background therapy) will power study for primary endpoint.","Interim analysis in ~100 patients not on background therapy corroborated prior ACT-AD Phase 2 findings.","Company targets enrollment completion mid-2023 and topline data in early 2024.","CEO cites strong balance sheet to execute through key data readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-019592","json":"https://secwatch.observer/filing/0000950170-22-019592.json","markdown":"https://secwatch.observer/filing/0000950170-22-019592.md","text":"https://secwatch.observer/filing/0000950170-22-019592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/0000950170-22-019592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/atha-20221017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:20:26.368301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}